Dyax Corp. To Host First Quarter 2012 Earnings Call And Webcast

Dyax Corp. (NASDAQ: DYAX) will host a webcast and conference call, including an open question and answer session, Tuesday, April 24, 2012. During the call, management will discuss the Company’s financial results for the first quarter ending March 31, 2012 and progress regarding its key value drivers - the KALBITOR ® (ecallantide) business and angioedema franchise, as well as the Licensing and Funded Research Program (LFRP).
                       

Date:
Tuesday, April 24, 2012

Time:
5:00 p.m. ET

Telephone Access:

Domestic callers, dial 877-674-2415; reference the Dyax conference call

International callers, dial 708-290-1364
No passcode required.

Online Access:

Go to the Investor Relations section of the Dyax website ( www.dyax.com) and follow instructions for accessing the live webcast. Participants may register in advance.
 

A replay of the conference call will be available through May 24, 2012 and may be accessed by dialing 855-859-2056. International callers should dial 404-537-3406. The replay passcode for all callers is 71194544. The webcast will be archived on the Dyax website for an indefinite period of time.

About Dyax

Dyax is a fully integrated biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs. The Company’s lead product, ecallantide, has been approved under the brand name KALBITOR in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.

Dyax is commercializing KALBITOR in the United States independently, and establishing strategic collaborations to develop and commercialize ecallantide for the treatment of HAE in key regions worldwide. Currently, Dyax has collaboration agreements for regions including Europe, Japan, Russia, the Middle East, Israel, North Africa, Australia, New Zealand, Latin America (excluding Mexico) and the Caribbean. The company is also exploring other potential indications for ecallantide, either alone or through collaborations, including drug-induced angioedema.

Ecallantide and other compounds in Dyax’s pipeline were identified using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the Licensing and Funded Research Program (LFRP). To date, the Company has entered into more than 75 agreements under the LFRP. Collectively, these agreements generate significant revenue for Dyax in the form of license fees, milestone payments and/or royalties. The success of the Company’s LFRP is illustrated by the program’s advanced licensee pipeline that includes 18 candidates in clinical development. Of those candidates, four are in Phase 3 clinical trials, four are in Phase 2 and ten are in Phase 1.

Dyax is headquartered in Burlington, Massachusetts. For online information about Dyax Corp., please visit www.dyax.com.

Copyright Business Wire 2010